OVERVIEW

Pushing the Threshold of Lipid Lowering: Incorporating the Evolving Database into Practice is organized by National Association for Continuing Education (NACE).

Start Date: 11/30/2019
Expiration Date: 11/29/2020

Accreditation:
The Association of Black Cardiologists designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.5 pharmacology hours.

Course Description:
Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. High risk patients, such as those with familial hypercholesterolemia (FH), a disorder associated with a mutation in the gene coding for proprotein convertase subtilisin/kexin type 9 (PCSK9), can particularly benefit from newer therapies. This activity will review the latest ACC/AHA Multisociety Guidelines on the management of blood cholesterol, how to incorporate the data of non-statin therapy for patients with high cardiovascular risk, and how to overcome barriers of PCSK9 therapy.

Learning Objectives:
After completing this program participants should be able to:
• Discuss the latest 2018 ACC/AHA Multi-society Guideline on the Management of Blood Cholesterol to reduce the risk of cardiovascular disease;
• Incorporate current data surrounding non-statin therapy into secondary prevention treatment strategies for patients with the highest cardiovascular risk;
• Overcome barriers to access for PCSK9 monoclonal antibody therapy.